Adaptive Biotechnologies Corp · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for Adaptive Biotechnologies Corp records an exercise / conversion involving Common Stock on October 5, 2026. The reported quantity was 11,881. The filing date is October 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.22 to $28.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F4

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F5

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F6

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F7

The option is fully vested and exercisable.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.